GMV is a Berlin-based company focused on malaria control and ultimate eradication through vaccination

We are focused on solving the challenges of large scale and low-cost industrialization of new malaria vaccines targeting both major malaria species, and seek to accelerate the development of new vaccines against malaria with a particular focus on vaccines that will aid with elimination and eradication campaigns. GMV staff have extensive experience in the management and conduct of vaccine development projects. In addition, we undertake horizon scanning for early awareness and potential access to new technologies, help partners with commercialisation opportunities, and help develop business cases for new investment.